Videos

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.

The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.

The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.

The chief medical officer of Forge Biologics discussed the potential advantages of the investigational combination therapy approach.

The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.

Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.

Paul discussed common symptoms and typical treatments for the 2 adverse events.

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.

Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.

The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the organization’s work with regulatory members to advance gene therapies towards review and approval.

The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the organization’s goals and strategies in educating regulatory decision-makers.

The chair of gynecologic oncology at Moffitt Cancer Center discussed advantages of targeting follicle stimulating hormone receptor with cell therapy for ovarian cancer.

The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.

Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.

The pediatrician from Royal Manchester Children’s Hospital discussed how further research in Gaucher disease can benefit the field of rare lysosomal diseases as a whole.

The chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.

The chief scientific officer of Excision BioTherapeutics discussed the phase 1/2 clinical trial of the CRISPR gene editing therapy.

The pediatrician from Royal Manchester Children’s Hospital discussed progress with the PROVIDE trial of PR001.

Rossano discussed unmet needs for patients with Danon disease and the potential of investigational gene therapy RP-A501.